Marc Beer has almost three decades of experience in pharmaceuticals, biotechnology, and diagnostics with his very own co-workers. Beer also works as an entrepreneur and a professional when it comes to sales and development. He was approached by numerous companies because of his intelligence, strategies, and executive talents.
Marc Beer holds a Bachelor of Science degree from Miami University in Ohio. Since the mid-1990s, Marc Beer has been concerned about women’s health issues while serving as CEO and Chairman of biotech development and medical science companies in the world. He worked for almost ten years at a pharmaceutical giant that manufactures the generic drug and medical devices worldwide namely Abbott Laboratories. After working at Abbot Laboratories, Beer became the founding CEO of ViaCell in April 2000. The biotechnology company specializes in the collection, development, and preservation of umbilical cord blood stem cells. Beer’s effective leadership skills lead the company to success, handling more than 300 employees.
Beer is also the founding Chairman of the board of directors of Good Start Genetics, Inc, a member of the audit committee of Minerva Neurosciences Inc., and a member of the Miami University Business Advisory Council. He was an active member of the board of directors in a biopharmaceutical company called Erytech Pharma, member of the Mass Life Science Board of the Commonwealth of Massachusetts, and in Biotechnology Industry Organization’s governing board. Furthermore, Beer held various positions in one of the largest biotechnology companies called Genzyme that acquire billions of revenue per year with more than 11,000 employees.
About Renovia Inc.
Almost 20 million women suffer from urinary incontinence in the United States of America, and 250 million women worldwide are also affected.
Renovia Inc. was Founded in 2016 by Co-Founder, Chairman, and Chief Executive Officer Mark Beer. The company was formed to commercialize and develop products that address rare diseases, diagnosis, and treatment for millions of women across the globe with pelvic floor disorders and urinary incontinence. It has an advanced medical device technology that enables visualization of the movement of a pelvic. Renovia’s FDA approved device such as the Leva Pelvic Digital Health System is a state of the art pipeline that strengthens pelvic floor muscles and treats mild to moderate urinary incontinence. It provides precise treatment and collects data on a woman’s pelvic health.
The Longwood Fund consists of leading health care investors that support Renovia. The funding is used to test a new generation of the Leva Pelvic Digital Health System, along with several therapeutic and diagnostic products in order to improve more lives of women who are affected with pelvic floor disorders.
Beer and his health care investors continue to innovate their digital health platform to ensure a greater understanding of pelvic floor disorders and low health care costs. Learn more: https://www.slideshare.net/MarcBeer